Brief: Theriva Biologics Reports Second Quarter 2023 Operational Highlights And Financial Results
Aug 8 (Reuters) - Theriva Biologics Inc TOVX.A :
* THERIVA™ BIOLOGICS REPORTS SECOND QUARTER 2023 OPERATIONAL
HIGHLIGHTS AND FINANCIAL RESULTS
* THERIVA BIOLOGICS INC - AS OF JUNE 30, 2023, THERIVA
BIOLOGICS
REPORTS $34.2 MILLION IN CASH, WHICH IS EXPECTED TO PROVIDE
RUNWAY INTO Q4 OF 2024
Source text for Eikon: ID:nGNX8FKxkM
Further company coverage: TOVX.A
Recent news on Theriva Biologics
See all newsTheriva Biologics Q2 net loss narrows on lower R&D costs, expenses
Brief: Theriva™ Biologics Announces Upcoming Presentation Of Additional Data From The Virage Phase 2B Clinical Trial Of Vcn-01 In Metastatic Pancreatic Cancer At Aacr 2026 Annual Meeting
Brief: Theriva Biologics Licenses Syn-020 To Rasayana Therapeutics For Multiple Indications
Brief: Theriva Biologics Implements 32% Workforce Reduction - SEC Filing
Brief: Theriva™ Biologics Announces Presentation Of Data From Vcn-01 Retinoblastoma Phase 1 Clinical Trial At Asco 2025